Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)
2.820
+0.030 (1.06%)
Apr 21, 2026, 4:08 PM HKT
HKG:1349 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,147 | 1,056 | 1,196 | 1,289 | 1,209 |
Short-Term Investments | - | - | - | 30 | - |
Cash & Short-Term Investments | 1,147 | 1,056 | 1,196 | 1,319 | 1,209 |
Cash Growth | 8.60% | -11.67% | -9.35% | 9.13% | -13.46% |
Accounts Receivable | 297.75 | 469.96 | 620.49 | 679.12 | 672.49 |
Other Receivables | 0.31 | 1.08 | 0.16 | 5.14 | 1.18 |
Receivables | 298.07 | 471.04 | 620.64 | 684.26 | 673.66 |
Inventory | 33.21 | 47.27 | 43.65 | 40.53 | 35.63 |
Other Current Assets | 7.16 | 32.18 | 9.24 | 25.1 | 9.77 |
Total Current Assets | 1,486 | 1,607 | 1,869 | 2,069 | 1,928 |
Property, Plant & Equipment | 477.25 | 503.53 | 475.33 | 351.51 | 301.92 |
Long-Term Investments | 229.07 | 257.49 | 287.53 | 306.37 | 327.86 |
Other Intangible Assets | 60.87 | 68.65 | 86.35 | 62.32 | 88.46 |
Long-Term Deferred Tax Assets | 131.41 | 133.28 | 100.87 | 85.9 | 79.22 |
Long-Term Deferred Charges | 4.41 | 9.28 | - | 43.09 | 36.12 |
Other Long-Term Assets | 2.12 | 7.5 | 57.18 | 57.62 | 19.64 |
Total Assets | 2,391 | 2,587 | 2,877 | 2,976 | 2,781 |
Accounts Payable | 6.07 | 10.67 | 8.05 | 7.43 | 8.17 |
Accrued Expenses | 171.35 | 167.57 | 36.86 | 34.67 | 53.78 |
Short-Term Debt | - | - | - | 101 | - |
Current Portion of Leases | 5.35 | 6.1 | 6.33 | 8.22 | 8.68 |
Current Income Taxes Payable | - | - | 1.61 | 1.63 | 10.4 |
Current Unearned Revenue | 5.41 | 8.34 | 0.26 | 0.31 | 348.87 |
Other Current Liabilities | 57.45 | 58.27 | 451.9 | 520.09 | 98.3 |
Total Current Liabilities | 245.62 | 250.95 | 505.02 | 673.34 | 528.2 |
Long-Term Leases | 9.34 | 14.43 | 10.95 | 15.6 | 22.59 |
Long-Term Unearned Revenue | 18.97 | 15.85 | 2.15 | 34.04 | 40.8 |
Total Liabilities | 273.93 | 281.23 | 518.12 | 722.99 | 591.58 |
Common Stock | 103.66 | 103.66 | 103.66 | 102.9 | 104.3 |
Additional Paid-In Capital | 1,290 | 1,290 | 1,289 | 1,225 | 1,265 |
Retained Earnings | 728.37 | 916.9 | 970.46 | 934.39 | 868.43 |
Treasury Stock | - | - | - | - | -40.82 |
Comprehensive Income & Other | -6.05 | -5.55 | -5.86 | -5.2 | -4.05 |
Total Common Equity | 2,116 | 2,305 | 2,358 | 2,257 | 2,193 |
Minority Interest | 0.43 | 0.71 | 1.01 | -4.08 | -3.36 |
Shareholders' Equity | 2,117 | 2,305 | 2,359 | 2,253 | 2,190 |
Total Liabilities & Equity | 2,391 | 2,587 | 2,877 | 2,976 | 2,781 |
Total Debt | 14.69 | 20.53 | 17.28 | 124.81 | 31.26 |
Net Cash (Debt) | 1,132 | 1,036 | 1,179 | 1,194 | 1,178 |
Net Cash Growth | 9.33% | -12.12% | -1.33% | 1.43% | -14.49% |
Net Cash Per Share | 1.09 | 1.00 | 1.14 | 1.16 | 1.13 |
Filing Date Shares Outstanding | 1,037 | 1,037 | 1,037 | 1,029 | 1,032 |
Total Common Shares Outstanding | 1,037 | 1,037 | 1,037 | 1,029 | 1,032 |
Working Capital | 1,240 | 1,356 | 1,364 | 1,396 | 1,400 |
Book Value Per Share | 2.04 | 2.22 | 2.27 | 2.19 | 2.12 |
Tangible Book Value | 2,055 | 2,236 | 2,271 | 2,195 | 2,104 |
Tangible Book Value Per Share | 1.98 | 2.16 | 2.19 | 2.13 | 2.04 |
Buildings | 396.73 | 368.53 | 199.22 | 198.52 | 198.52 |
Machinery | 500.03 | 504.91 | 388.63 | 341.74 | 322.86 |
Construction In Progress | 0.19 | 7.2 | 229.96 | 122.37 | 48.9 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.